AstraZeneca on Thursday said its Covid-19 prophylaxis drug is 83% effective in reducing the risk of symptomatic Covid-19 infections six months after being given, signaling that the antibody cocktail could be used as an effective means of preventing severe disease in individuals who may not develop a robust immune response to Covid-19 vaccines....
A separate follow-up of the prophylaxis’ phase three trials showed that the drug eliminated the risk of severe Covid-19 and deaths among all recipients over six months after a dose was administered. The drugmaker noted that the trials used a 300-milligram dose of AZD7442 administered into the muscle to individuals who had not been exposed to Covid-19.
The antibody cocktail could prove to be an effective tool to protect people who may not develop a robust immune response after receiving Covid-19 vaccines.AstraZeneca’s chief of research and development, Mene Pangalos, said: “AZD7442 is the only long-acting antibody with Phase III data to demonstrate benefit in both pre-exposure prophylaxis and treatment of Covid-19 with one dose.”700,000. That’s the total number of doses of the antibody drug that AstraZeneca has agreed to supply to the U.S.
May God continue to bless you ma'am I never believe trading is going to work out for me because I have lost a lot in different places I know one day they will face the judgment. I really appreciate you for your transparency and trust markdonaldlisaT
honestly the vast majority of people dont get their vaccine based on protection. they get their vaccine bec ause they dont want to live with restrictions set up by the state.